SCHEMBL19686926

SCHEMBL19686926

Cc1cc(C)n(-c2nc(CF)cc(NC3CCCC(F)(F)C3)n2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.55
KCNN3 Q9UGI6 1/20 0.55
ALOX15 P16050 2/20 0.39
NPSR1 Q6W5P4 3/20 0.38
LMNA P02545 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 2/20 0.37
ADORA2A P29274 8/20 0.37
ADORA1 P30542 7/20 0.37
NR2F2 P24468 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
S1PR2 O95136 1/20 0.36
XBP1 P17861 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687167 0.91 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686594 0.88 KCNN2 (0.57) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19687390 0.85 KCNN2 (0.51) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686501 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL21144006 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL31127093 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686502 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686503 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686506 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA
SCHEMBL19686504 0.83 KCNN2 (0.54) KCNN2KCNN3ALOX15NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885ALOX15 2894/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885ALOX15 2894/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885ALOX15 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.